Scott Crowder, MD
Psychiatry · Wilmington, NCNPI 1710084983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 85 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$454
- Supernus Pharmaceuticals, Inc.$299
- Adlon Therapeutics L.p.$274
- Axsome Therapeutics, Inc.$250
- Collegium Pharmaceutical, Inc.$147
- Johnson & Johnson$118
- plus $381 from 10 others
Across 12 payments — averaging $1215.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$8K
- Pfizer$7K
What the payments were for
- Food & beverage$1,89799%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$233
How this compares
$1,924 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 12 | $7,363 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 73 | $2,067 |
| Duloxetine Hcl | 115 | $1,612 |
| Lorazepam | 88 | $851 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 43 | $830 |
| Bupropion Hcl SrBupropion Hcl | 58 | $794 |
| Aripiprazole | 56 | $739 |
| Bupropion XlBupropion Hcl | 26 | $727 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $727 |
| Lamotrigine | 52 | $613 |
| Lurasidone Hcl | 13 | $603 |
| Escitalopram Oxalate | 59 | $568 |
| Trazodone Hcl | 48 | $483 |
| Fluoxetine Hcl | 24 | $466 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $444 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Wilmington
- Paul BuongiornoWilmington$208K
- Rano MathewWilmington$15K
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.